Roivant's experimental drug mosliciguat met its primary and secondary endpoints in a 16-week Phase 2 study for pulmonary hypertension.
Key facts
- •The Phase 2 study for mosliciguat lasted 16 weeks.
- •The drug achieved a 56% reduction in pulmonary vascular resistance versus a placebo.
- •Patients experienced a 35-meter improvement in six-minute walk distance.
- •NT-proBNP levels, a marker for heart failure, were reduced by 53%.
Roivant announced on Tuesday that its experimental drug, mosliciguat, successfully met the goals of a mid-stage clinical study. The drug is being developed to treat a specific form of pulmonary hypertension, a serious lung disease.
By the numbers
Study results and endpoints
In the 16-week Phase 2 trial, mosliciguat demonstrated a statistically significant 56% reduction in pulmonary vascular resistance compared to a placebo. This metric measures blood pressure and flow within the artery connecting the heart to the lungs. The study also met its key secondary endpoints. Patients treated with the drug showed a 35-meter improvement in six-minute walk distance compared to the placebo group, as well as a 53% reduction in NT-proBNP, which serves as a blood-based marker for heart failure.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by STAT News.
